Literature DB >> 10996459

Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration.

M Quik1, Y Polonskaya, A Gillespie, G K Lloyd, J W Langston.   

Abstract

Our previous studies showed that alpha4, alpha6, alpha7, beta2, beta3 and beta4 nicotinic acetylcholine receptor messenger RNAs are present in monkey substantia nigra, with a particularly intense and localized labelling of the alpha6 and beta3 subunit messenger RNAs to this brain region. Because loss of nigrostriatal neurons is a central feature of Parkinson's disease and evidence suggests that nicotinic agonists potentiate antiparkinsonian effects of L-dopa, experiments were done to determine whether nicotinic receptor subunit messenger RNAs and binding sites were altered in the basal ganglia after nigrostriatal degeneration. Squirrel monkeys (Saimiri sciureus) were rendered parkinsonian by systemic injection of the selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Behavioral studies showed that this treatment decreased baseline motor activity to 36+/-11% of control. One month after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration, caudate and putamen dopamine levels were reduced to 51+/-15% and 43+/-6% of control, respectively, while the number of tyrosine hydroxylase-positive neurons in the substantia nigra was 75+/-6% of control. Despite the reduction in nigral cell number after nigrostriatal degeneration, there were no changes in alpha4, alpha7, beta2 and beta4 messenger RNA levels in the substantia nigra. In contrast, alpha6 mRNA levels were significantly increased (143+/-10%) and the beta3 transcript decreased (62+/-6%) in the substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Declines were also observed in [125I]epibatidine binding in both the caudate-putamen and substantia nigra, with no change in alpha7 receptor binding. These results may suggest a dissociation in the regulation of receptor messenger RNA and binding sites, and/or that there are differential alterations in the different receptor subtypes measured using [125I]epibatidine. The changes in the two nicotinic receptor subunit messenger RNAs, alpha6 and beta3, which exhibit a selective localization to the substantia nigra, may indicate that nicotinic receptors containing these subunits are altered after nigrostriatal degeneration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996459     DOI: 10.1016/s0306-4522(00)00244-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

Review 3.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

4.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

5.  Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.

Authors:  M Quik; Y Polonskaya; J M Kulak; J M McIntosh
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

6.  The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.

Authors:  Danhui Zhang; Matthew McGregor; Michael W Decker; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2014-07-17       Impact factor: 4.030

7.  Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.

Authors:  Maryka Quik; Carla Campos; Neeraja Parameswaran; J William Langston; J Michael McIntosh; Michael Yeluashvili
Journal:  J Mol Neurosci       Date:  2009-08-15       Impact factor: 3.444

8.  Functional alpha7-containing nicotinic acetylcholine receptors localize to cell bodies and proximal dendrites in the rat substantia nigra pars reticulata.

Authors:  Olga V Poisik; Jian-xin Shen; Susan Jones; Jerrel L Yakel
Journal:  J Physiol       Date:  2008-03-01       Impact factor: 5.182

9.  Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbens.

Authors:  Xiomara A Perez; Jason Ly; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2012-05-04       Impact factor: 4.030

10.  Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.

Authors:  Masroor Shariff; Maryka Quik; Joan Holgate; Michael Morgan; Omkar L Patkar; Vincent Tam; Arnauld Belmer; Selena E Bartlett
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.